Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Resea... ( TUSTIN Calif. Jan. 6 /- AMDL Inc....)

Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Research Report

Date:1/6/2009

TUSTIN, Calif., Jan. 6 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), a vertically integrated pharmaceutical company with operations in China and the US, announced today industry analyst Lauren Rudd has issued a strong buy recommendation for AMDL in his year-end financial research report on the Company.

The report projects a 12-month target price of $5.00 for AMDL and highlights the Company's:

    -- Consistent, positive historical financial performance over the past
       four years
    -- Most recent operational changes and business updates, including an
       updated overview of AMDL's China-based subsidiary Jade Pharmaceuticals,
       Inc.
    -- FY2009 product pipeline
    -- FY2009 plans for the AMDL ELISA DR-70(R) (FDP) cancer monitoring test;
       best-selling Human Placenta Extract (HPE) anti-aging product line; and
       MYHPV Chip(R) diagnostic test kit which detects approximately 28
       different strains of the Human Papilloma Virus.

The research report also provides a thorough peer group comparison with valuation analyses, views and opinions on AMDL's projected financial performance for the 2009 fiscal year, and historical financials.

According to Mr. Rudd, "AMDL has taken major initiatives to build its strengths while reorganizing top management and still producing respectable financials which has resulted in AMDL being one of the most under priced stocks we have seen in a long time."

A full copy of the report is available for downloading online at http://www.ruddreport.com or by contacting Ms. Kristine Szarkowitz, AMDL's Director Investor Relations, at kszarkowi
'/>"/>

0

GOOD

Page: 1 2
Related medicine news :

1. Consumer Reports: Big Promises of Some Infomercial Exercise Machines Fall Flat; Plus, Set Up a Home Gym for Under $100
2. Cardium Reports on Exchange Listing With NYSE Alternext US
3. CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte Closes
4. Joint Commission Reports Positive Survey Results for CHA
5. Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability
6. Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability
7. Risks and Benefits of Egg Donation Reported
8. LegalView Updates its Baxter Heparin Information Portal with Conflicting News Reports on the Possible Dangers
9. Despite Sagging Economy, Viamedic Reports Solid Online Sales for Erectile Dysfunction Drugs
10. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
11. Published reports inaccurate concerning alcohol consumption during pregnancy

Post Your Comments:

Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Resea...( TUSTIN Calif. Jan. 6 /- AMDL Inc....),Health